RIPK1 and stroke disorder: Similar results were obtained in experimental stroke models; both Nec-1 and SB216763 (a glycogen synthase kinase-3 β inhibitor) attenuated ischemia-induced reactive astrogliosis by reducing the interaction between RIPK1 and glycogen synthase kinase 3β (GSK3β) and inhibiting inflammatory cytokines [57].